Target intelligence / Profile preview

Microbial Cell Wall / Membrane

Molecular classification
Other (structural carbohydrate-protein-lipid complexes), Not an individual "receptor," "enzyme," etc., but composed of molecular targets such as peptidoglycan, lipopolysaccharide, teichoic acids, various membrane proteins
01

Overview

The **microbial cell wall** is a rigid, porous structure composed mostly of **peptidoglycan in bacteria**, providing protection against osmotic lysis, maintaining cell shape, and acting as a filter for large molecules. Many antibiotics exploit the essential and unique components of the microbial cell wall (such as peptidoglycan synthesis enzymes) as high-value drug targets because these structures are absent in human cells, reducing cross-reactivity and toxicity. The **microbial membrane** (often the cytoplasmic membrane or, for Gram-negative bacteria, also the outer membrane) is vital for functions such as substance transport, energy metabolism, and anchoring of biosynthetic enzymes; membrane integrity is also a target for some antibiotics. Because these are structural assemblies, not individual proteins or receptors, "microbial cell wall / membrane" is considered a non-specific, umbrella target category comprising multiple underlying molecular targets (e.g., penicillin-binding proteins, Mur family enzymes, lipid A, LPS biosynthesis enzymes, etc.)

Other names
Bacterial cell wallBacterial membraneMicrobial membraneProkaryotic cell envelope
02

Mechanism of action

Inhibition of cell wall biosynthesis (e.g., blocking peptidoglycan crosslinking) Disruption of membrane integrity/permeability Inhibition of peptidoglycan unit transport or polymerization

03

Biological functions

Maintain cell shapeOsmotic protectionSelective permeabilityStructural integrityPathogenicity and virulence
04

Disease associations

Infection (central to bacterial survival, virulence, and antibiotic targeting)
05

Safety considerations

Targeting bacterial cell wall/membrane has low off-target toxicity due to absence in human cells, but resistance development is a major therapeutic challengeSome drugs (e.g., polymyxins) have toxicity concerns (kidney, neurotoxicity)
06

Interacting drugs

β-lactams (penicillins, cephalosporins, carbapenems, monobactams)

7 more in the full profile.

07

Biomarkers

Not typically used directly as clinical biomarkers, but components like lipoteichoic acids, peptidoglycan fragments, and LPS can be experimentally detected and sometimes serve as indirect infection markers

Beyond the preview

Go deeper on Microbial Cell Wall / Membrane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microbial Cell Wall / Membrane.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call